• Something wrong with this record ?

Antitumor carboplatin is more toxic in tumor cells when photoactivated: enhanced DNA binding

J. Mlcouskova, J. Stepankova, V. Brabec,

. 2012 ; 17 (6) : 891-8.

Language English Country Germany

Document type Journal Article, Research Support, Non-U.S. Gov't

Carboplatin, an analogue of "classical" cis-diamminedichloridoplatinum(II) (cisplatin), is a widely used second-generation platinum anticancer drug. Cytotoxicity of cisplatin and carboplatin is mediated by platinum-DNA adducts. Markedly higher concentrations of carboplatin are required, and the rate of adduct formation is considerably slower. The reduced toxic effects in tumor cells and a more acceptable side-effect profile are attributable to the lower reactivity of carboplatin with nucleophiles, since the cyclobutanedicarboxylate ligand is a poorer leaving group than the chlorides in cisplatin. Recently, platinum complexes were shown to be particularly attractive as potential photochemotherapeutic anticancer agents. Selective photoactivation of platinum complexes by irradiation of cancer cells may avoid enhancement of toxic side-effects, but may increase toxicity selectively in cancer cells and extend the application of photoactivatable platinum complexes to resistant cells and to a wider range of cancer types. Therefore, it was of interest to examine whether carboplatin can be affected by irradiation with light to the extent that its DNA binding and cytotoxic properties are altered. We have found that carboplatin is converted to species capable of enhanced DNA binding by UVA irradiation and consequently its toxicity in cancer cells is markedly enhanced. Recent advances in laser and fiber-optic technologies make it possible to irradiate also internal organs with light of highly defined intensity and wavelength. Thus, carboplatin is a candidate for use in photoactivated cancer chemotherapy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13012666
003      
CZ-PrNML
005      
20130411105658.0
007      
ta
008      
130404s2012 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00775-012-0906-z $2 doi
035    __
$a (PubMed)22638735
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Mlcouskova, Jarmila $u Department of Biophysics, Faculty of Science, Palacky University, Olomouc, Czech Republic.
245    10
$a Antitumor carboplatin is more toxic in tumor cells when photoactivated: enhanced DNA binding / $c J. Mlcouskova, J. Stepankova, V. Brabec,
520    9_
$a Carboplatin, an analogue of "classical" cis-diamminedichloridoplatinum(II) (cisplatin), is a widely used second-generation platinum anticancer drug. Cytotoxicity of cisplatin and carboplatin is mediated by platinum-DNA adducts. Markedly higher concentrations of carboplatin are required, and the rate of adduct formation is considerably slower. The reduced toxic effects in tumor cells and a more acceptable side-effect profile are attributable to the lower reactivity of carboplatin with nucleophiles, since the cyclobutanedicarboxylate ligand is a poorer leaving group than the chlorides in cisplatin. Recently, platinum complexes were shown to be particularly attractive as potential photochemotherapeutic anticancer agents. Selective photoactivation of platinum complexes by irradiation of cancer cells may avoid enhancement of toxic side-effects, but may increase toxicity selectively in cancer cells and extend the application of photoactivatable platinum complexes to resistant cells and to a wider range of cancer types. Therefore, it was of interest to examine whether carboplatin can be affected by irradiation with light to the extent that its DNA binding and cytotoxic properties are altered. We have found that carboplatin is converted to species capable of enhanced DNA binding by UVA irradiation and consequently its toxicity in cancer cells is markedly enhanced. Recent advances in laser and fiber-optic technologies make it possible to irradiate also internal organs with light of highly defined intensity and wavelength. Thus, carboplatin is a candidate for use in photoactivated cancer chemotherapy.
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové látky $x chemie $x farmakologie $x účinky záření $x toxicita $7 D000970
650    _2
$a vazebná místa $x účinky léků $7 D001665
650    _2
$a karboplatina $x chemie $x farmakologie $x účinky záření $x toxicita $7 D016190
650    _2
$a skot $7 D002417
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a DNA $x chemie $x účinky léků $7 D004247
650    _2
$a poškození DNA $x účinky léků $7 D004249
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a screeningové testy protinádorových léčiv $7 D004354
650    _2
$a lidé $7 D006801
650    _2
$a kinetika $7 D007700
650    _2
$a fotochemické procesy $x účinky záření $7 D055668
650    _2
$a plazmidy $7 D010957
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    _2
$a nádorové buňky kultivované $7 D014407
650    _2
$a ultrafialové záření $7 D014466
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Stepankova, Jana $u -
700    1_
$a Brabec, Viktor $u -
773    0_
$w MED00005752 $t Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry $x 1432-1327 $g Roč. 17, č. 6 (2012), s. 891-8
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22638735 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20130404 $b ABA008
991    __
$a 20130411105929 $b ABA008
999    __
$a ok $b bmc $g 975864 $s 810947
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 17 $c 6 $d 891-8 $i 1432-1327 $m JBIC, Journal of biological inorganic chemistry $n J Biol Inorg Chem $x MED00005752
LZP    __
$a Pubmed-20130404

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...